These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 33546755)
1. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Kay J; Jaworski J; Wojciechowski R; Wiland P; Dudek A; Krogulec M; Jeka S; Zielinska A; Trefler J; Bartnicka-Maslowska K; Krajewska-Wlodarczyk M; Klimiuk PA; Lee SJ; Bae YJ; Yang GE; Yoo JK; Furst DE; Keystone E Arthritis Res Ther; 2021 Feb; 23(1):51. PubMed ID: 33546755 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Furst DE; Jaworski J; Wojciechowski R; Wiland P; Dudek A; Krogulec M; Jeka S; Zielinska A; Trefler J; Bartnicka-Maslowska K; Krajewska-Wlodarczyk M; Klimiuk PA; Lee SJ; Kim SH; Bae YJ; Yang GE; Yoo JK; Kay J; Keystone E Rheumatology (Oxford); 2022 Apr; 61(4):1385-1395. PubMed ID: 34142111 [TBL] [Abstract][Full Text] [Related]
3. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis. Fleischmann RM; Alten R; Pileckyte M; Lobello K; Hua SY; Cronenberger C; Alvarez D; Bock AE; Sewell KL Arthritis Res Ther; 2018 Aug; 20(1):178. PubMed ID: 30111357 [TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial. Fleischmann RM; Alvarez DF; Bock AE; Cronenberger C; Vranic I; Zhang W; Alten R Arthritis Res Ther; 2021 Sep; 23(1):248. PubMed ID: 34563243 [TBL] [Abstract][Full Text] [Related]
5. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Genovese MC; Glover J; Greenwald M; Porawska W; El Khouri EC; Dokoupilova E; Vargas JI; Stanislavchuk M; Kellner H; Baranova E; Matsunaga N; Alten R Arthritis Res Ther; 2019 Dec; 21(1):281. PubMed ID: 31831079 [TBL] [Abstract][Full Text] [Related]
6. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects. Yu KS; Jang IJ; Lim HS; Hong JH; Kim MG; Park MK; Cho DY; Park MS; Chung JY; Ghim JL; Lee S; Yoon SK; Kwon IS; Lee SJ; Kim SH; Bae YJ; Cha JB; Furst DE; Keystone E; Kay J Clin Transl Sci; 2021 Jul; 14(4):1280-1291. PubMed ID: 33503313 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults. Haranaka M; Tanaka T; Kim S; Bae Y; Jeon D; Choi E; Cha J; Lee S; Ogama Y Immunotherapy; 2023 Feb; 15(3):149-161. PubMed ID: 36748363 [TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Cohen SB; Alten R; Kameda H; Hala T; Radominski SC; Rehman MI; Palaparthy R; Schumacher K; Schmitt S; Hua SY; Ianos C; Sewell KL Arthritis Res Ther; 2018 Jul; 20(1):155. PubMed ID: 30053896 [TBL] [Abstract][Full Text] [Related]
10. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Cohen SB; Alonso-Ruiz A; Klimiuk PA; Lee EC; Peter N; Sonderegger I; Assudani D Ann Rheum Dis; 2018 Jun; 77(6):914-921. PubMed ID: 29514803 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Cohen S; Genovese MC; Choy E; Perez-Ruiz F; Matsumoto A; Pavelka K; Pablos JL; Rizzo W; Hrycaj P; Zhang N; Shergy W; Kaur P Ann Rheum Dis; 2017 Oct; 76(10):1679-1687. PubMed ID: 28584187 [TBL] [Abstract][Full Text] [Related]
12. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. Edwards CJ; Monnet J; Ullmann M; Vlachos P; Chyrok V; Ghori V Clin Rheumatol; 2019 Dec; 38(12):3381-3390. PubMed ID: 31396834 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study. Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670 [TBL] [Abstract][Full Text] [Related]
14. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial. Leng X; Leszczyński P; Jeka S; Liu SY; Liu H; Miakisz M; Gu J; Kilasonia L; Stanislavchuk M; Yang X; Zhou Y; Dong Q; Rezk M; Mitroiu M; Addison J; Zeng X Lancet Rheumatol; 2024 Jan; 6(1):e40-e50. PubMed ID: 38258678 [TBL] [Abstract][Full Text] [Related]
15. An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. Cohen S; Pablos JL; Pavelka K; Müller GA; Matsumoto A; Kivitz A; Wang H; Krishnan E Arthritis Res Ther; 2019 Mar; 21(1):84. PubMed ID: 30922373 [TBL] [Abstract][Full Text] [Related]
16. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH MAbs; 2018; 10(6):934-943. PubMed ID: 30010481 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47. Smolen JS; Trefler J; Racewicz A; Jaworski J; Zielińska A; Krogulec M; Jeka S; Wojciechowski R; Kolossa K; Dudek A; Krajewska-Włodarczyk M; Hrycaj P; Klimiuk PA; Burmester GR; Kim S; Bae Y; Yang G; Jung Y; Hong J; Keystone E RMD Open; 2024 Oct; 10(4):. PubMed ID: 39424404 [TBL] [Abstract][Full Text] [Related]
18. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. Jamshidi A; Gharibdoost F; Vojdanian M; Soroosh SG; Soroush M; Ahmadzadeh A; Nazarinia MA; Mousavi M; Karimzadeh H; Shakibi MR; Rezaieyazdi Z; Sahebari M; Hajiabbasi A; Ebrahimi AA; Mahjourian N; Rashti AM Arthritis Res Ther; 2017 Jul; 19(1):168. PubMed ID: 28728599 [TBL] [Abstract][Full Text] [Related]
19. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study. Wiland P; Jeka S; Dokoupilová E; Brandt-Jürgens J; Miranda Limón JM; Cantalejo Moreira M; Cabello RV; Jauch-Lembach J; Thakur A; Haliduola H; Brueckmann I; Gaylis NB BioDrugs; 2020 Dec; 34(6):809-823. PubMed ID: 33119861 [TBL] [Abstract][Full Text] [Related]
20. Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293. Fleischmann RM; Alvarez DF; Bock AE; Cronenberger C; Vranic I; Zhang W; Alten R RMD Open; 2021 Apr; 7(2):. PubMed ID: 33883254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]